The capital will be used by the company to expand adoption of its internal surgical adhesive in Germany and additional European markets.

Designed for use in large flap surgeries, the CE-marked TissuGlu Surgical Adhesive eliminates or reduces fluid accumulation and the need for post surgical drains allowing for more natural healing and potentially faster recovery, according to Cohera.

In addition, the company will use funds to support its first No-Drain clinical study for TissuGlu in the US.

The company is also planning to commence human clinical trials using its Sylys Surgical Sealant, designed to help surgeons reduce anastomotic leakage, a most serious complication of bowel repair during performing colorectal procedures, in Europe.

Kern Whelan Capital founder and general partner and Kern Medical IV manager John Kern said, "The innovative technology that has made TissuGlu so successful illustrates the potential impact that its Sylys product will have in the investor community, another first-of-its-kind product in a billion dollar industry."